想象一位深受焦虑障碍困扰的来访者，咨询师可能会用这样的表述引导："让我们一起探索当你感到心 跳加速时，身体里那个'危险警报器'是如何被误触发的。"短短一句话，却蕴含着多重心理学原理。 它首先通过认知重构，将生理反应—心跳加速，重新定义为心理机制，危险警报器的误判，巧妙削弱了 症状带来的威胁感，让来访者不再对自身反应感到恐惧和无助； 其次，借助"警报器"这一隐喻，将抽象的情绪具象化，为来访者搭建起理解和管理情绪的桥梁，帮助他 们在混沌的情绪中找到抓手； 这样的表述还为后续的行为实验埋下伏笔，咨询师可能会据此布置"记录触发场景"的作业，将语言层面 的干预切实转化为可操作的改变。 （原标题：别被伪专业建议误导！精准干预与大众科普中间有边有界） 在心理健康领域，我们常常会遇到两种截然不同的语言体系：心理咨询师与来访者对话时的专业用语， 以及各类科普文章、媒体报道中面向大众的表述。这两种语言就像同一枚硬币的两面，虽同属心理学科 普范畴，却有着天壤之别的功能与使命，背后隐藏着深刻的专业逻辑与传播智慧。 心理咨询中的语言，堪称"靶向干预"的精准工具，严格遵循"症状-机制-干预"的医学模型。 就像网络上曾流行的"治愈"建议： ...

Core Insights - BrainsWay has entered into a strategic equity financing agreement with Stella MSO, LLC to enhance access to mental health care and raise awareness of innovative treatments [1][2] - The investment in Stella is part of a broader strategy to make minority-stake investments in high-performing mental health providers across the U.S. [2] - BrainsWay will invest $5 million in Stella, acquiring a minority position in the company through preferred, annually compounding securities [4] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology [5] - The company has received FDA clearance for three indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5] - BrainsWay aims to increase global awareness and access to Deep TMS through ongoing clinical trials and scientific advancements [5] Stella Overview - Stella is an interventional psychiatry practice focused on effective mental health protocols for conditions such as severe trauma, stress, anxiety, and depression [6] - The organization has a strong reputation for clinical excellence and operational strength, having treated over 30,000 patients across more than 20 clinics [1][6] - Stella's partnership with BrainsWay is expected to accelerate its growth and enhance patient care [3][5]

Core Insights - BrainsWay Ltd. has entered into a strategic equity financing agreement with Stella MSO, LLC to enhance access to innovative mental health treatments [1][2] - The investment of $5 million will provide BrainsWay with a minority position in Stella, aimed at supporting the interventional psychiatry space [4][2] - This partnership is expected to accelerate growth and improve patient care through Stella's established network of mental health clinics [3][5] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep TMS™ technology [5] - The company has received FDA clearance for three indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5] - BrainsWay is focused on advancing neuroscience and increasing global awareness of its treatment options [5] Stella Overview - Stella is an interventional psychiatry practice that addresses severe trauma, stress, anxiety, and depression through a multidisciplinary approach [6] - The organization has a strong reputation for clinical excellence and operational strength, having treated over 30,000 patients [1][6] - Stella aims to expand access to transformative mental health care through its network of clinics [3][5]

Core Insights - LifeStance Health Group, Inc. is one of the largest providers of outpatient mental health care in the United States [3] - The company will present at the 46th Annual Goldman Sachs Healthcare Conference on June 10, 2025 [1] - The presentation will be led by CEO Dave Bourdon and CFO Ryan McGroarty, and will be available via live webcast [1][2] Company Overview - LifeStance Health was founded in 2017 and focuses on providing virtual and in-person outpatient mental health care for various age groups [3] - The company employs approximately 7,500 mental health professionals and operates over 550 centers across 33 states [3] - LifeStance aims to improve access to affordable and personalized mental health care, helping individuals lead healthier lives [3]

Core Insights - LifeStance Health has appointed Vaughn Paunovich as Chief Technology Officer, effective June 9, 2025, to lead the company's technology strategy and enhance the patient and clinician experience [1][2] - Paunovich has over 25 years of experience in healthcare technology, previously serving as EVP at Amwell and holding various leadership roles at UnitedHealth Group, including Chief Information Officer of Optum Health [2][3] - The transition follows the departure of Pablo Pantaleoni, who played a significant role in LifeStance's digital transformation since 2020 and will assist Paunovich during the transition [3] Company Overview - LifeStance Health, founded in 2017, is one of the largest providers of virtual and in-person outpatient mental healthcare in the U.S., operating over 550 centers across 33 states [4] - The company employs approximately 7,500 mental health professionals, including psychiatrists, psychologists, and therapists, with a mission to improve access to affordable and personalized mental healthcare [4]

Core Viewpoint - LifeStance Health Group (LFST) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, particularly influenced by institutional investors [4][6]. - LifeStance Health is projected to earn -$0.10 per share for the fiscal year ending December 2025, reflecting a year-over-year change of 33.3% [8]. - Over the past three months, the Zacks Consensus Estimate for LifeStance Health has increased by 31.6%, indicating a positive trend in earnings expectations [8]. Investment Implications - The upgrade to Zacks Rank 1 positions LifeStance Health in the top 5% of Zacks-covered stocks, suggesting potential for higher stock prices in the near term due to improved earnings outlook [10]. - Rising earnings estimates and the corresponding rating upgrade imply an enhancement in the company's underlying business, which should attract investor interest and drive the stock price higher [5][10].

Lifestance Health Group (LFST) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Company Participants Monica Prokocki - Vice President, Investor RelationsDavid Bourdon - CEORyan McGroarty - CFOCraig Hettenbach - Executive DirectorRyan Daniels - Group Head–Healthcare Technology and ServicesRichard Close - Managing DirectorSteve Dechert - AVP Conference Call Participants Jamie Perse - Equity Research AnalystBrian Tanquilut - Equity Research Analyst - Healthcare Services Operator Good day everyone and thank you f ...

Reimagining Mental Health Q1 2025 Earnings Presentation • May 7, 2025 Forward-Looking Statements DISCLAIMERS Cautionary Note Regarding Forward-Looking Statements This presentation and related oral statements, including during any question and answer portion of the presentation, contain forward-looking statements about LifeStance Health Group, Inc. and its subsidiaries ("LifeStance") and the industry in which LifeStance operates, including statements regarding: full-year and second quarter guidance and manag ...

SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the first quarter ended March 31, 2025. (All results compared to prior-year comparative period, unless otherwise noted)Q1 2025 Highlights and FY 2025 Outlook Revenue of $333.0 million increased 11% compared to revenue of $300.4 millionClinician base increased 10% to 7,535 clinicians, a sequential net inc ...

2025 First Quarter Earnings Presentation May 6, 2025 2025 FIRST QUARTER EARNINGS PRESENTATION 2 Disclaimer $64 54% $39 34% Revenue1 Composition USD, Millions PAYOR DTE CONSUMER Gross Profit and % Margin USD, Millions (1) Revenue is presented on an as-reported basis. This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this presentation that do not relate to maers of historical fact sh ...